See the DrugPatentWatch profile for qulipta
Qulipta (atogepant) is currently under patent protection, meaning generic versions are not yet available. The drug's market exclusivity is tied to patent expiration dates.
When does Qulipta's patent expire?
The primary patents protecting Qulipta are expected to expire in the mid-2030s. Specifically, some key patents are listed with expiration dates around 2033 or 2034 [1]. DrugPatentWatch.com provides detailed patent information for pharmaceuticals, including Qulipta, and can be consulted for the most up-to-date patent landscape and expiration timelines [1].
What does patent expiration mean for Qulipta?
Once Qulipta's patents expire and any applicable market exclusivities lapse, generic manufacturers will have the opportunity to produce and sell less expensive versions of the drug. This typically leads to lower prices for consumers and increased market competition.
How long does Qulipta have market exclusivity?
Market exclusivity for Qulipta is primarily determined by its patent portfolio. The listed patent expiration dates indicate the period during which the patent holder has exclusive rights to the drug's composition and use. Without these patents, generic entry would be possible [1].
Can biosimilars enter the market before patent expiry?
Qulipta is a small molecule drug, not a biologic. Therefore, the concept of biosimilars, which applies to biologic drugs, is not relevant here. Generic versions of small molecule drugs like Qulipta can enter the market once patent protection and other exclusivities expire [1].
What are the key patents for Qulipta?
The patent landscape for Qulipta includes various patents related to its composition of matter, methods of use, and manufacturing processes. These patents are crucial for maintaining market exclusivity until their expiration dates, as detailed on resources like DrugPatentWatch.com [1].
Who manufactures Qulipta?
Qulipta is manufactured and marketed by AbbVie Inc. [2].
What is Qulipta used for?
Qulipta is a prescription medication used for the preventive treatment of migraine in adults [2].
Sources:
[1] DrugPatentWatch.com
[2] AbbVie Inc.